Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Sanigen Partner on NGS-Based Food Safety Testing in South Korea

NEW YORK – South Korea's Sanigen said on Wednesday that it has partnered with Illumina to develop next-generation sequencing panels for food safety testing. The company will also become a distributor of Illumina's sequencing technology in South Korea for the food safety and microbiology market.

The firms will develop NGS panels that can rapidly detect 16 types of foodborne pathogens from about 400 samples. Sanigen said it expects the panels to be available in the third quarter. Financial and other details of the deal were not disclosed.

"NGS offers an unprecedented opportunity to the food market to improve safety. We are delighted to partner with Sanigen whose deep expertise in this sector will be a driving force in bringing new accurate and rapid tests to the food safety market," Gretchen Weightman, VP and general manager for Illumina in Asia-Pacific and Japan, said in a statement.

The agreement follows other deals Illumina has struck with firms on assay development. In May, the San Diego-based company partnered with Australia's Microba on human gut microbiome sequencing, and in April, it announced a collaboration with Kartos Therapeutics to develop an NGS-based TP53 companion diagnostic for that firm's MDM2 inhibitor.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.